Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.

Li X, Fang P, Li Y, Kuo YM, Andrews AJ, Nanayakkara G, Johnson C, Fu H, Shan H, Du F, Hoffman NE, Yu D, Eguchi S, Madesh M, Koch WJ, Sun J, Jiang X, Wang H, Yang X.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1090-100. doi: 10.1161/ATVBAHA.115.306964. Epub 2016 Apr 28.

PMID:
27127201
2.
3.

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial.

Hu C, Tompson D, Magee M, Chen Q, Liu YM, Zhu W, Zhao H, Gross AS, Liu Y.

PLoS One. 2015 Oct 14;10(10):e0139862. doi: 10.1371/journal.pone.0139862. eCollection 2015.

4.

A Framework for Local Mechanical Characterization of Atherosclerotic Plaques: Combination of Ultrasound Displacement Imaging and Inverse Finite Element Analysis.

Akyildiz AC, Hansen HH, Nieuwstadt HA, Speelman L, De Korte CL, van der Steen AF, Gijsen FJ.

Ann Biomed Eng. 2016 Apr;44(4):968-79. doi: 10.1007/s10439-015-1410-8. Epub 2015 Sep 23.

5.

Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging.

Kataoka Y, Puri R, Nicholls SJ.

Cardiovasc Diagn Ther. 2015 Aug;5(4):280-9. doi: 10.3978/j.issn.2223-3652.2015.05.06. Review.

6.

Lp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative Macrophages.

He S, Chousterman BG, Fenn A, Anzai A, Nairz M, Brandt M, Hilgendorf I, Sun Y, Ye YX, Iwamoto Y, Tricot B, Weissleder R, Macphee C, Libby P, Nahrendorf M, Swirski FK.

Circ Heart Fail. 2015 Sep;8(5):980-7. doi: 10.1161/CIRCHEARTFAILURE.115.002334. Epub 2015 Jul 31.

7.

Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

Garg PK, McClelland RL, Jenny NS, Criqui MH, Greenland P, Rosenson RS, Siscovick DS, Jorgensen N, Cushman M.

Atherosclerosis. 2015 Jul;241(1):176-82. doi: 10.1016/j.atherosclerosis.2015.05.006. Epub 2015 May 16.

PMID:
26004387
8.

Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.

Cai A, Li G, Chen J, Li X, Li L, Zhou Y.

BMC Cardiovasc Disord. 2015 Feb 26;15:14. doi: 10.1186/s12872-015-0001-9.

9.

The role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitis.

Crawford GL, Boldison J, Copland DA, Adamson P, Gale D, Brandt M, Nicholson LB, Dick AD.

PLoS One. 2015 Apr 15;10(4):e0122093. doi: 10.1371/journal.pone.0122093. eCollection 2015.

10.

Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.

Han X, Wang T, Zhang J, Liu X, Li Z, Wang G, Song Q, Pang D, Ouyang H, Tang X.

Biol Open. 2015 Apr 2;4(5):661-5. doi: 10.1242/bio.201410900.

11.
12.

Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.

Lenaerts A, Barry CE 3rd, Dartois V.

Immunol Rev. 2015 Mar;264(1):288-307. doi: 10.1111/imr.12252. Review.

13.

Circulating biologically active oxidized phospholipids show on-going and increased oxidative stress in older male mice.

Liu J, Li W, Chen R, McIntyre TM.

Redox Biol. 2013;1:110-4. doi: 10.1016/j.redox.2012.11.011. Epub 2013 Jan 30.

14.

Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application.

Linden F, Domschke G, Erbel C, Akhavanpoor M, Katus HA, Gleissner CA.

Front Physiol. 2014 Nov 21;5:455. doi: 10.3389/fphys.2014.00455. eCollection 2014. Review.

15.

Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.

Chung H, Kwon HM, Kim JY, Yoon YW, Rhee J, Choi EY, Min PK, Hong BK, Rim SJ, Yoon JH, Lee SJ, Park JK, Kim MH, Jo M, Yang JH, Lee BK.

Yonsei Med J. 2014 Nov;55(6):1507-15. doi: 10.3349/ymj.2014.55.6.1507.

16.

Evolving targets for lipid-modifying therapy.

Do RQ, Nicholls SJ, Schwartz GG.

EMBO Mol Med. 2014 Aug 29;6(10):1215-30. doi: 10.15252/emmm.201404000. Review.

17.

Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events.

Steen DL, O'Donoghue ML.

Cardiol Ther. 2013 Dec;2(2):125-34. doi: 10.1007/s40119-013-0022-3. Epub 2013 Sep 25.

18.

Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina.

Tsaknis G, Tsangaris I, Ikonomidis I, Tsantes A.

Dis Markers. 2014;2014:831364. doi: 10.1155/2014/831364. Epub 2014 Jun 19. Review.

19.

Unraveling the PAF-AH/Lp-PLA2 controversy.

Stafforini DM, Zimmerman GA.

J Lipid Res. 2014 Sep;55(9):1811-4. doi: 10.1194/jlr.E052886. Epub 2014 Jul 9. No abstract available.

20.

Imaging plaques to predict and better manage patients with acute coronary events.

Garcia-Garcia HM, Jang IK, Serruys PW, Kovacic JC, Narula J, Fayad ZA.

Circ Res. 2014 Jun 6;114(12):1904-17. doi: 10.1161/CIRCRESAHA.114.302745. Review.

Items per page

Supplemental Content

Write to the Help Desk